Biocon Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Biocon Ltd gained for a fifth straight session today. The stock is quoting at Rs 430.55, up 2.76% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.33% on the day, quoting at 23767.5. The Sensex is at 75657.84, up 0.34%. Biocon Ltd has gained around 22.75% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has gained around 9.77% in last one month and is currently quoting at 24551.05, up 0.44% on the day. The volume in the stock stood at 56.13 lakh shares today, compared to the daily average of 46.75 lakh shares in last one month.

The benchmark May futures contract for the stock is quoting at Rs 431.7, up 2.65% on the day. Biocon Ltd is up 26.86% in last one year as compared to a 5.01% slide in NIFTY and a 13.99% slide in the Nifty Pharma index.

The PE of the stock is 285.14 based on TTM earnings ending March 26.

Powered by Capital Market - Live News

Biocon Ltd is up for a third straight session in a row. The stock is quoting at Rs 417.35, up 3.7% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.38% on the day, quoting at 23468.45. The Sensex is at 74886.66, up 0.44%. Biocon Ltd has added around 19.12% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has added around 6.63% in last one month and is currently quoting at 23840.9, up 0.34% on the day. The volume in the stock stood at 68.88 lakh shares today, compared to the daily average of 40.85 lakh shares in last one month.

The benchmark May futures contract for the stock is quoting at Rs 419.55, up 3.75% on the day. Biocon Ltd is up 23.4% in last one year as compared to a 4.86% fall in NIFTY and a 11.37% fall in the Nifty Pharma index.

The PE of the stock is 273.57 based on TTM earnings ending March 26.

Powered by Capital Market - Live News

Biocon Ltd is up for a fifth straight session today. The stock is quoting at Rs 386.7, up 1.16% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.67% on the day, quoting at 24164.3. The Sensex is at 77254.26, down 0.76%. Biocon Ltd has gained around 11.86% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has gained around 9.02% in last one month and is currently quoting at 24135.5, down 0.02% on the day. The volume in the stock stood at 42.2 lakh shares today, compared to the daily average of 29.37 lakh shares in last one month.

The benchmark May futures contract for the stock is quoting at Rs 385.55, up 0.26% on the day. Biocon Ltd is up 17.22% in last one year as compared to a 0.65% jump in NIFTY and a 14.52% jump in the Nifty Pharma index.

The PE of the stock is 318.83 based on TTM earnings ending December 25.

Powered by Capital Market - Live News

Revenue from operations rose by 2.26% year-on-year (YoY) to Rs 4,517 crore during the period under review.

EBIDTA fell by 3.77% to Rs 1,073 crore while EBIDTA margin declined by 200 basis points YoY to 23% in Q4 FY26.

Profit before tax in Q4 FY26 stood at Rs 248 crore, down by 49.2% from Rs 487 crore in Q4 FY25.

For FY26, the company has recorded consolidated net profit and revenue from operations of Rs 386 crore (down 61.9% YoY) and Rs 16,927 crore (up 10.9% YoY), respectively.

Kiran Mazumdar-Shaw, executive chairperson, Biocon, said: ?Biocon closed FY26 on a strong note despite a complex geopolitical environment.

We delivered margin expansion along with 13% YoY growth in operating revenue, excluding the one-time impact of generic lenalidomide sales last year. This performance reflects the resilience of our business and disciplined execution through a pivotal year of integration.

We have created a unified biopharma entity by integrating biosimilars business with generics formulations and APIs business. The combined business has a stronger balance sheet, improved leverage metrics and a more global commercial footprint.

Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.

The scrip advanced 2.43% to currently trade at Rs 391.90 on the BSE.

Powered by Capital Market - Live News